Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 12—December 2024
Research Letter
Zoonotic Potential of Chronic Wasting Disease After Adaptation in Intermediate Species
Suggested citation for this article
Abstract
Chronic wasting disease (CWD) is an emerging disease in Europe. We report an increase in interspecies transmission capacity and zoonotic potential of a moose CWD isolate from Europe after passage in an ovine prion protein–expressing host. Those results indicated some CWD prions could acquire enhanced zoonotic properties following adaptation in an intermediate species.
Chronic wasting disease (CWD) is a highly contagious prion disease affecting members of the Cervidae family. CWD is widely spread across North America, where it endangers the survival of free-ranging cervid populations. In Europe, CWD was reported in a reindeer (Rangifer tarandus tarandus) from Norway in 2016 (1). Since 2016, several cases have been reported in Norway, Sweden, and Finland in multiple species, including reindeer, red deer (Cervus elaphus), and moose (Alces alces) (2).
Whereas CWD strains circulating in North America exhibit some uniformity (3), the cases found in Europe are more variable. Transmission into rodent models has revealed multiple CWD strains that are apparently different than strains in North America, and moose cases in Norway have demonstrated biochemical patterns distinct from previous cases in Europe (4). We characterized the interspecies transmission potential of 1 moose CWD isolate from Norway (Norwegian Veterinary Institute identification no. 16–60-P153) (4) by intracerebral injection of mouse models expressing the normal prion protein (PrPC) sequences from several species (Figure, panel A).
We anesthetized and inoculated 6–10-week-old mice with 2 mg of equivalent tissue (20 µL of 10% brain homogenate) in the right parietal lobe. We monitored the inoculated animals daily and humanely euthanized animals at the onset of clinical signs or after the preestablished endpoint of 700 days postinfection (dpi). We conducted a systematic proteinase K–resistant prion protein (PrPres) detection by using Western blot.
Inoculation of the original CWD isolate did not cause the propagation of detectable prions in Tg340 mice expressing methionine (TgMet) or Tg361 mice expressing valine (TgVal) at position 129 of human PrPC. We did not observe PrPres in brain tissue or disease occurrence in bovine PrPC-expressing mice (BoTg110) after intracerebral inoculation of the CWD isolate (Table; Figure, panel B).
We inoculated the CWD isolate in Tg338 mice, which overexpress ovine PrP ≈8 times. At 612 and 717 dpi (Table), 2 of 12 animals showed clinical signs of prion disease and we detected PrPres accumulation in their brain tissue (Figure, panel B). Of note, the 2 animals showed different PrPres banding patterns, with the nonglycosylated band migrating to 19 kDa in the first mouse and to 21 kDa in the second. Both PrPres-containing brains transmitted disease with 100% efficacy to second-passage Tg338 mice, which contained 21-kDa PrPres in their brains (Figure, panel B). A third passage resulted in the incubation period shortening (95 ± 5 dpi). Our observations are consistent with a progressive adaptation of the moose CWD prion to the ovine-PrPC expressing model and suggest moose CWD prions in Europe may have an intrinsic capability to propagate in ovine species with the VRQ genotype.
We next determined whether adaptation of this moose CWD agent to Tg338 altered its capacity to cross species barriers. For that purpose, we inoculated Tg338-adapted moose CWD prions (passaged twice in Tg338) to the same panel of PrPC-expressing mice models. Inoculation of the Tg338-adapted isolate to BoTg110 resulted in 100% disease transmission that showed a banding pattern and intermediate molecular weight from 19–21 kDa (Figure, panel C; Appendix Figure) and an incubation period of 431 ± 32 dpi (Table), which suggested the lack of a major transmission barrier. In addition, 1 of 8 inoculated TgMet mice showed clinical signs at 561 dpi (Table). PrPres in the brain of that mouse was revealed by a mixed 19 + 21 kDa banding pattern (Figure, panel C). A second passage in TgMet is underway.
Inoculation of TgVal resulted in efficient transmission (5/6 animals); the mean incubation period was 483 ± 35 dpi (Table) and accumulation was 21 kDa PrPres (Figure, panel C). On second passage, transmission was 100% and we observed a shorter incubation period (311 ± 12 dpi).
The incubation periods and PrPres biochemical profiles of the CWD prions that propagated in the TgMet and TgVal mice greatly differed from those observed in mice inoculated with the most prevalent human prion strains or with classic bovine spongiform encephalopathy (BSE), sheep-adapted BSE, or Tg338-adapted c-BSE (Table; Figure, panel D). Those results might suggest this CWD-derived prion strain differs from other strains documented in those models. Further investigation is necessary.
The evolution of moose CWD zoonotic potential after its passage in an ovine PrPC-expressing host is reminiscent of the well-documented altered capacities of the c-BSE agent to cross the human species barrier after adaptation in sheep and goats (9). The codon 129-dependent response to infection of humanized mice with Tg338-adapted CWD is also compatible with studies demonstrating the role of this polymorphism in susceptibility to prions (10).
In summary, our results demonstrate the potential capacity of some CWD agents to transmit to sheep or other farmed animals. Our results highlight the need to experimentally assess and monitor this transmission risk under natural exposure conditions. In addition, the dramatic changes of the zoonotic capacity of the CWD isolate we documented from Europe clearly demonstrate the risk adaptation and propagation of cervid prions into farmed animals represents. Although additional studies are needed to characterize these emerging agents, our findings have major potential implications for animal and public health.
Dr. Barrio is a research scientist with Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement. His research interests include animal and human prion diseases and other neurodegenerative disorders linked to misfolded proteins.
Acknowledgments
Experiments were performed in compliance with institutional, national, and European guidelines and approved by the local Ecole Nationale Vétérinaire de Toulouse ethics committee.
This work was funded by the International Coordination of Research on Infectious Animal Diseases, a European Research Area Networks co-funded by the European Union’s Horizon 2020 research and innovation program through project Tackling Chronic Wasting Disease in Europe (grant no. 862605), the European Union’s “HORIZON EUROPE” program through project WiLiMan-ID (grant no. 101083833), Agence National de la Recherche through project European Union-Chronic Wasting Disease (grant no. ANR-20-CE35-0015), and the European Regional Development Fund via the Interreg V-A Spain-France-Andorra program through projects REDPRION (grant no. EFA 148/16) and NEURO-COOP (grant no. EFA 031/01).
References
- Benestad SL, Mitchell G, Simmons M, Ytrehus B, Vikøren T. First case of chronic wasting disease in Europe in a Norwegian free-ranging reindeer. Vet Res. 2016;47:88. DOIPubMedGoogle Scholar
- Tranulis MA, Gavier-Widén D, Våge J, Nöremark M, Korpenfelt SL, Hautaniemi M, et al. Chronic wasting disease in Europe: new strains on the horizon. Acta Vet Scand. 2021;63:48. DOIPubMedGoogle Scholar
- Nonno R, Di Bari MA, Pirisinu L, D’Agostino C, Vanni I, Chiappini B, et al. Studies in bank voles reveal strain differences between chronic wasting disease prions from Norway and North America. Proc Natl Acad Sci U S A. 2020;117:31417–26. DOIPubMedGoogle Scholar
- Pirisinu L, Tran L, Chiappini B, Vanni I, Di Bari MA, Vaccari G, et al. Novel type of chronic wasting disease detected in moose (Alces alces), Norway. Emerg Infect Dis. 2018;24:2210–8. DOIPubMedGoogle Scholar
- Cassard H, Torres JM, Lacroux C, Douet JY, Benestad SL, Lantier F, et al. Evidence for zoonotic potential of ovine scrapie prions. Nat Commun. 2014;5:5821. DOIPubMedGoogle Scholar
- Hill AF, Joiner S, Wadsworth JD, Sidle KC, Bell JE, Budka H, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain. 2003;126:1333–46. DOIPubMedGoogle Scholar
- Huor A, Espinosa JC, Vidal E, Cassard H, Douet JY, Lugan S, et al. The emergence of classical BSE from atypical/Nor98 scrapie. Proc Natl Acad Sci U S A. 2019;116:26853–62. DOIPubMedGoogle Scholar
- Torres JM, Espinosa JC, Aguilar-Calvo P, Herva ME, Relaño-Ginés A, Villa-Diaz A, et al. Elements modulating the prion species barrier and its passage consequences. PLoS One. 2014;9:
e89722 . DOIPubMedGoogle Scholar - Padilla D, Béringue V, Espinosa JC, Andreoletti O, Jaumain E, Reine F, et al. Sheep and goat BSE propagate more efficiently than cattle BSE in human PrP transgenic mice. PLoS Pathog. 2011;7:
e1001319 . DOIPubMedGoogle Scholar - Deslys JP, Marcé D, Dormont D. Similar genetic susceptibility in iatrogenic and sporadic Creutzfeldt-Jakob disease. J Gen Virol. 1994;75:23–7. DOIPubMedGoogle Scholar
Figures
Table
Suggested citation for this article: Barrio T, Benestad SL, Douet J-Y, Huor A, Lugan S, Aron N, et al. Zoonotic potential of chronic wasting disease after adaptation in intermediate species. Emerg Infect Dis. 2024 Dec [date cited]. https://doi.org/10.3201/eid3012.240536
Original Publication Date: November 20, 2024
Table of Contents – Volume 30, Number 12—December 2024
EID Search Options |
---|
Advanced Article Search – Search articles by author and/or keyword. |
Articles by Country Search – Search articles by the topic country. |
Article Type Search – Search articles by article type and issue. |
Please use the form below to submit correspondence to the authors or contact them at the following address:
Tomás Barrio, Unité Mixte de Recherche de l’Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement 1225 Interactions Hôtes-Agents Pathogènes, , 23 chemin des Capelles 31076 Toulouse, Franceemail:tomas.barrio@envt.fr
Top